FDA approves BioCryst drug to treat HAE swelling disorder; stock jumps 14% Posted by WRAL TechWire | Dec 4, 2020 Shares in Triangle pharmaceutical firm BioCryst surged 14% Friday morning after the company disclosed FDA approval of its drug to treat a rare swelling disorder. Read More